Skip to content
Study details
Enrolling now

Study to Evaluate Budesonide for Ulcerative Colitis in Children

Bausch Health Americas, Inc.
NCT IDNCT04314375ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

70

Study length

about 3.8 years

Ages

5–17

Locations

4 sites in CA, IN, NC +1

About this study

Researchers are testing a treatment called budesonide, which is a type of medication, to see if it helps children with mild to moderate ulcerative colitis. The trial will last 1370 days and involve about 70 children who have active ulcerative colitis.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take High Dose Budesonide
  • 2.Take Low Dose Budesonide
  • 3.Take Placebo
PhasePhase 4
DrugLow Dose Budesonide
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low6%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

ALIMENTARY TRACT AND METABOLISM

Drug routes

oral (Delayed Release Oral Capsule)

Body systems

Gastroenterology